NCT06635148

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 274 (estimated)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Conditions

• Geographic Atrophy
• Macular Degeneration

Interventions

Type	Name	Description
DRUG	JNJ-81201887	No study intervention will be administered as part of this LTE study.
OTHER	Sham Procedure	No study intervention will be administered as part of this LTE study.

Timeline

• Start date: 2024-09-19
• Primary completion: 2029-08-24
• Completion: 2030-07-16
• First posted: 2024-10-10
• Last updated: 2026-04-13

Locations

104 sites across 18 countries: United States, Australia, Belgium, Canada, China, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study